Welcome to our dedicated page for EVELO BIOSCIENCES news (Ticker: EVLO), a resource for investors and traders seeking the latest updates and insights on EVELO BIOSCIENCES stock.
Evelo Biosciences, Inc. (Nasdaq: EVLO) is a clinical-stage biotechnology company committed to transforming the lives of patients worldwide by developing innovative medicines known as monoclonal microbials. These therapies are orally administered and designed to modulate systemic immunology and biology by interacting directly with human cells in the gut.
Evelo’s groundbreaking approach leverages the small intestinal axis (SINTAX) to develop medicines that hold promise for a wide range of diseases, including autoimmune, immunoinflammatory, metabolic, neurological, and neuroinflammatory conditions, as well as cancer. The company's monoclonal microbials are poised to revolutionize traditional drug discovery and development by enhancing speed, reducing costs, and increasing the success rate of therapeutic outcomes.
Recent achievements at Evelo include the ongoing development of EDP2939, a next-generation product candidate for moderate psoriasis, which builds on the positive Phase 2 clinical data of its predecessor, EDP1815. Despite challenges in recent trials, Evelo remains dedicated to advancing its SINTAX platform and pursuing strategic alternatives for further development and potential partnerships.
Financially, Evelo has recently secured additional financing and restructured its debt, providing the resources needed to continue its clinical programs into 2024. The company aims to deliver therapies that are not only effective and safe but also affordable, addressing the unmet needs of millions of patients with inflammatory diseases.
Founded within VentureLabs® by Flagship Pioneering, Evelo Biosciences is a testament to innovative biotechnology with a mission to discover and develop transformative medicines for a wide array of conditions.
For more information, please visit www.evelobio.com or contact their investor and media relations teams at ir@evelobio.com and media@evelobio.com.
Evelo Biosciences (Nasdaq: EVLO) will host a fireside chat at the Jefferies London Healthcare Conference on November 16, 2021, at 6:20 a.m. ET. The event will highlight Evelo's innovative SINTAX™ medicines, aimed at treating inflammatory diseases and cancers through orally delivered therapies. A live audio webcast will be available on the company's website, with replays accessible for 30 days. Evelo is progressing four product candidates designed to positively impact immune and neurological systems, reinforcing its commitment to developing effective and affordable treatments.
Evelo Biosciences (Nasdaq: EVLO) reported positive Phase 2 data for EDP1815 in psoriasis, advancing towards registration studies. The company is set to initiate dosing in a Phase 2 trial for EDP1815 in atopic dermatitis in Q4 2021, following FDA's lifting of a clinical hold. Preclinical data for EDP1867 in neuroinflammatory diseases shows promise. Financially, cash reserves increased to $95.9 million, but net loss rose to $33.7 million, or $0.63 per share for Q3 2021, highlighting a significant increase in R&D and G&A expenses.
Evelo Biosciences, a clinical-stage biotechnology company, announced a conference call on October 28, 2021, at 8:30 a.m. ET to discuss its Q3 2021 financial results and business highlights. The call can be accessed by dialing 866-795-3242 (domestic) or 409-937-8909 (international). Evelo focuses on developing SINTAX™ medicines for inflammatory diseases and cancer, with candidate products EDP1815, EDP1867, EDP2939, and EDP1908 currently in development. For more details, visit evelobio.com.
Evelo Biosciences (Nasdaq: EVLO) presented preclinical data for EDP1867 at ECTRIMS 2021, showing promising results in reducing disease severity and relapse incidence in mouse models of multiple sclerosis. EDP1867, an orally administered SINTAX medicine, appears to overcome blood-brain barrier limitations, offering new pathways for treating neuroinflammatory diseases. These results support ongoing development efforts for EDP1867 and highlight its potential for wide applications in inflammatory and neuroinflammatory conditions.
Evelo Biosciences announced positive Phase 2 results for EDP1815 in treating mild to moderate psoriasis, showing a statistically significant improvement in the Psoriasis Area and Severity Index (PASI) score. 29% of patients achieved PASI-50 compared to 12% on placebo. Safety data were comparable to placebo, with no serious adverse events reported. EDP1815 is advancing towards registration studies, aiming to transform treatment for inflammatory diseases. A conference call will discuss the next steps for EDP1815 and its implications for patient care.
Evelo Biosciences (Nasdaq:EVLO) will host a fireside chat at the Cantor Global Healthcare Conference on September 27, 2021, at 1:20 p.m. ET. The event will be available via live audio webcast on their website, with a replay accessible for 30 days after. Evelo is a clinical stage biotechnology company focused on developing orally delivered medicines targeting the small intestinal axis for systemic effects. Their pipeline includes four product candidates for treating inflammatory diseases and cancer, emphasizing effective and affordable therapies.
Evelo Biosciences has received a new U.S. patent (No. 11,090,341) for pharmaceutical compositions containing Veillonella parvula bacteria, including its clinical candidate EDP1867, currently in Phase 1b trials for atopic dermatitis. This patent strengthens Evelo's IP portfolio related to SINTAX™, a novel approach targeting the small intestinal axis. The patent also covers extracellular vesicles derived from Veillonella. Dr. Mark Bodmer highlighted the significance of patent eligibility for these innovative oral medicines, reinforcing Evelo's commitment to developing effective treatments.
Evelo Biosciences (Nasdaq: EVLO) announced the appointment of Iain McInnes, M.B.Ch.B, Ph.D., to its Board of Directors on September 7, 2021. Professor McInnes is a recognized expert in rheumatology and clinical immunology, with significant experience in developing treatments for inflammatory diseases. His expertise is expected to enhance Evelo's focus on advancing its product candidates, EDP1815 and EDP1867, for psoriasis and atopic dermatitis. Evelo aims to leverage its innovative SINTAX™ platform for transformative therapeutic benefits.
Evelo Biosciences reported its second quarter 2021 financial results on July 29, highlighting key developments in its clinical trials and leadership. The company is set to release Phase 2b data for EDP1815 in psoriasis and initiate a Phase 2 trial in atopic dermatitis, both anticipated in 3Q 2021. Cash and cash equivalents increased to $123.3 million, while net loss rose to $31.6 million. The strategic appointment of Mark Plinio as Chief Commercial Officer aims to bolster commercial efforts as multiple clinical data readouts are expected in the coming months.
Evelo Biosciences (Nasdaq:EVLO) announced a conference call scheduled for July 29, 2021, at 8:30 a.m. ET to discuss its second quarter 2021 financial results and business highlights. The call can be accessed by dialing 866-795-3242 (domestic) or 409-937-8909 (international), using conference ID 1658301. A live webcast will also be available on Evelo's website, and an archived version will be accessible for 30 days post-event.
Evelo is focused on developing orally delivered medicines targeting the small intestinal axis, with four product candidates aimed at inflammatory diseases and cancer.
FAQ
What is the current stock price of EVELO BIOSCIENCES (EVLO)?
What is the market cap of EVELO BIOSCIENCES (EVLO)?
What does Evelo Biosciences specialize in?
What diseases are Evelo's medicines targeting?
What is the SINTAX platform?
What is EDP2939?
Who founded Evelo Biosciences?
Has Evelo secured financing recently?
What recent trials has Evelo conducted?
What is the mission of Evelo Biosciences?
How can I contact Evelo Biosciences for investor information?
Where can I find more information about Evelo Biosciences?
